Mark D’Amico

3.9k total citations · 1 hit paper
15 papers, 3.3k citations indexed

About

Mark D’Amico is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mark D’Amico has authored 15 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Mark D’Amico's work include Cancer-related Molecular Pathways (9 papers), Cancer-related gene regulation (4 papers) and Cell death mechanisms and regulation (3 papers). Mark D’Amico is often cited by papers focused on Cancer-related Molecular Pathways (9 papers), Cancer-related gene regulation (4 papers) and Cell death mechanisms and regulation (3 papers). Mark D’Amico collaborates with scholars based in United States, Israel and Canada. Mark D’Amico's co-authors include Richard G. Pestell, Chris Albanese, Avri Ben‐Ze'ev, Inbal Simcha, Jacob Zhurinsky, Michael Shtutman, Maofu Fu, Richard J. Lee, Genichi Watanabe and Kongming Wu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Mark D’Amico

15 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway

1999 1.9k citations Michael Shtutman, Jacob Zhurinsky et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark D’Amico United States	14	2.7k	1.0k	461	360	352	15	3.3k
Sandra Peiró Spain	28	2.1k 0.8×	992 1.0×	576 1.2×	237 0.7×	359 1.0×	42	2.9k
Ron Firestein United States	35	2.9k 1.1×	1.2k 1.2×	679 1.5×	304 0.8×	516 1.5×	59	4.3k
Valeriana Di Castro Italy	33	2.0k 0.7×	833 0.8×	641 1.4×	257 0.7×	427 1.2×	56	3.5k
Anna C. Schinzel United States	21	2.3k 0.9×	738 0.7×	375 0.8×	157 0.4×	511 1.5×	39	3.1k
Rui‐An Wang United States	29	2.2k 0.8×	1.1k 1.1×	604 1.3×	720 2.0×	284 0.8×	56	3.1k
Esther Zwick Germany	11	2.3k 0.9×	1.2k 1.2×	388 0.8×	265 0.7×	297 0.8×	12	3.7k
Karen Swisshelm United States	30	2.1k 0.8×	702 0.7×	650 1.4×	602 1.7×	240 0.7×	60	3.1k
Laura Rosanò Italy	35	2.1k 0.8×	915 0.9×	671 1.5×	250 0.7×	418 1.2×	63	3.7k
Benilde Jiménez Spain	28	2.2k 0.8×	568 0.6×	841 1.8×	215 0.6×	396 1.1×	49	3.1k
Norbert Prenzel Germany	9	2.2k 0.8×	1.3k 1.3×	424 0.9×	255 0.7×	325 0.9×	9	3.6k

Countries citing papers authored by Mark D’Amico

Since Specialization

Citations

This map shows the geographic impact of Mark D’Amico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D’Amico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D’Amico more than expected).

Fields of papers citing papers by Mark D’Amico

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D’Amico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D’Amico. The network helps show where Mark D’Amico may publish in the future.

Co-authorship network of co-authors of Mark D’Amico

This figure shows the co-authorship network connecting the top 25 collaborators of Mark D’Amico. A scholar is included among the top collaborators of Mark D’Amico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D’Amico. Mark D’Amico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Rao, Mahadev, Mathew C. Casimiro, Michael P. Lisanti, et al.. (2008). Inhibition of cyclin D1 gene transcription by Brg-1. Cell Cycle. 7(5). 647–655. 17 indexed citations

Chung, Joon‐Yong, Till Braunschweig, Ilya Mazo, et al.. (2007). Expression of EIF3-p48/INT6, TID1 and Patched in cancer, a profiling of multiple tumor types and correlation of expression. Journal of Biomedical Science. 14(3). 395–405. 18 indexed citations

Wu, Kongming, Mark D’Amico, Chenguang Wang, et al.. (2005). A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. Investigational New Drugs. 23(4). 299–309. 4 indexed citations

D’Amico, Mark, Kongming Wu, Maofu Fu, et al.. (2004). The Inhibitor of Cyclin-Dependent Kinase 4a/Alternative Reading Frame ( INK4a/ARF ) Locus Encoded Proteins p16INK4a and p19ARF Repress Cyclin D1 Transcription through Distinct cis Elements. Cancer Research. 64(12). 4122–4130. 33 indexed citations

Albanese, Chris, Kongming Wu, Mark D’Amico, et al.. (2003). IKKα Regulates Mitogenic Signaling through Transcriptional Induction of Cyclin D1 via Tcf. Molecular Biology of the Cell. 14(2). 585–599. 131 indexed citations

Wu, Kongming, Ying Yang, Chenguang Wang, et al.. (2003). DACH1 Inhibits Transforming Growth Factor-β Signaling through Binding Smad4. Journal of Biological Chemistry. 278(51). 51673–51684. 107 indexed citations

Huang, Erich, Seiichi Ishida, Jennifer Pittman, et al.. (2003). Gene expression phenotypic models that predict the activity of oncogenic pathways. Nature Genetics. 34(2). 226–230. 189 indexed citations

D’Amico, Mark, Kongming Wu, Dolores Di Vizio, et al.. (2003). The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.. PubMed. 63(12). 3395–402. 25 indexed citations

Wu, Kongming, Chenguang Wang, Mark D’Amico, et al.. (2002). Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.. PubMed. 1(9). 695–706. 52 indexed citations

10.

Lee, Richard J., Chris Albanese, Maofu Fu, et al.. (2000). Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. Molecular and Cellular Biology. 20(2). 672–683. 305 indexed citations

11.

Albanese, Chris, Anne T. Reutens, Boumediene Bouzahzah, et al.. (2000). Sustained mammary gland‐directed, ponasterone A‐inducible expression in transgenic mice. The FASEB Journal. 14(7). 877–884. 48 indexed citations

12.

Shtutman, Michael, Jacob Zhurinsky, Inbal Simcha, et al.. (1999). The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proceedings of the National Academy of Sciences. 96(10). 5522–5527. 1913 indexed citations breakdown →

13.

Albanese, Chris, Mark D’Amico, Anne T. Reutens, et al.. (1999). Activation of the cyclin D1 Gene by the E1A-associated Protein p300 through AP-1 Inhibits Cellular Apoptosis. Journal of Biological Chemistry. 274(48). 34186–34195. 160 indexed citations

14.

Joyce, David A., Boumediene Bouzahzah, Maofu Fu, et al.. (1999). Integration of Rac-dependent Regulation of Cyclin D1 Transcription through a Nuclear Factor-κB-dependent Pathway. Journal of Biological Chemistry. 274(36). 25245–25249. 253 indexed citations

15.

Peña, Pilar de la, Anne T. Reutens, Chris Albanese, et al.. (1999). Activator Protein-2 Mediates Transcriptional Activation of the CYP11A1 Gene by Interaction with Sp1 Rather than Binding to DNA. Molecular Endocrinology. 13(8). 1402–1416. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact